Investors in NovoCure (NASDAQ:NVCR) Have Seen Notable Returns of 97% Over the Past Year

Simply Wall StJan 8 20:49

SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?

Seeking AlphaJan 6 06:32

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

NovocureJan 3 13:00

Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $46

Futu NewsJan 2 20:32 · Ratings

Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025

BreakingsDec 17, 2024 19:03

NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.

BenzingaDec 14, 2024 04:49